Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension

A Network Meta-Analysis

Huijun Zhang, MD, Xiaobing Li, MD, Jiancheng Huang, MD, Hongying Li, MD, Zhenyu Su, MD, and Jun Wang, MD

Abstract: Prostacyclin analogs, such as epoprostenol, treprostinil, iloprost, and beraprost, have long been used for pulmonary arterial hypertension (PAH) treatment, yet their relative efficiency remains disputed.

Eligible randomized controlled trials (RCTs) involving the 4 therapies mentioned above were retrieved from PubMed, Embase, and Cochrane (up to August 1, 2015). Odds ratios (ORs) were estimated for dichotomous data (mortality, functional class (FC) amelioration, and discontinuation); standardized mean differences (SMDs) with 95% confidence intervals (CIs) were estimated for continuous data (6-min walk distance [6-MWD]).

Patients taking epoprostenol were anticipated to demonstrate more expedient 6-MWD than those taking placebo when network meta-analysis (NMA) was implemented (SMD = 52.19; 95% CI: 24.28–113.39), the trend of which was identical with that of pairwise meta-analysis (SMD = 69.28; 95% CI: 10.43–128.98). Nonetheless, the prominent advantages of treprostinil over placebo (SMD = 30.15; 95% CI: 19.29–40.01) in 6-MWD could not be replicated by NMA. Furthermore, direct and indirect (NMA) comparisons also differed in FC amelioration. For example, the superiority of epoprostenol over placebo as evident with the use of NMA (OR = 42.79; 95% CI: 10.63–301.98) could not be confirmed by pairwise meta-analysis. As suggested by indirect comparisons among 4 prostanoids, epoprostenol appears to result in remarkably favorable FC amelioration compared to other regimens (all P < 0.05). Participants taking beraprost were more probable to withdraw in comparison with those administered with iloprost (OR = 10.07; 95% CI: 1.47–160.65).

Taking mortality, FC amelioration, discontinuation, and 6-MWD into account, epoprostenol could be recommended as an alternative treatment for patients with moderate/advanced PAH.

Medicine 95(4):e2575

Abbreviations: 6-MWD = 6-min walk distance, CIs = confidence intervals, ERAs = endothelin receptor antagonists, FC = functional class, NMA = network meta-analysis, ORs = odds ratios, PAH = pulmonary arterial hypertension, PDE-5Is = phosphodiesterase type 5 inhibitors, PH = pulmonary hypertension, RCTs = randomized controlled trials, SMDs = standard mean differences, WMD = weighted mean difference.

INTRODUCTION

Pulmonary arterial hypertension (PAH), which belongs to pulmonary hypertension (PH) group I, gradually develops as a result of enhanced obstruction in pulmonary vascular and it is accompanied by ascending pressure in pulmonary arterial.1 PAH patients, with prevalence averaging 0.003%, can develop right-sided heart collapse, leading to premature demise.2–4 According to the Registry to Evaluate Early and Long-term PAH (REVEAL), PAH primarily breaks down into Associated PAH (APAH, 51%) and Idiopathic PAH (IPAH, 46%), along with Familial PAH (FPAH, 2.7%), pulmonary venoocclusive disease (PVOD, 0.4%), pulmonary capillary hemangiomatosis (PCH, < 0.1%), and persistent pulmonary hypertension of the newborn (PPHN, 0.0%).5

To counter the multiple forms of PAH in various populations, a number of therapeutic regimes were developed. For example, endothelin receptor antagonists (ERAs) and phosphodiesterase type 5 inhibitors (PDE-5Is) have been approved to treat relatively mild PAH. ERAs are likely to impose restrictions on the interaction between endothelin and smooth muscle cell receptors; PDE-5Is serve to restrain decomposition of a second messenger (ie cGMP) involved in nitric oxide (NO) pathways, thereby prompting vasodilation.6,7 Prostacyclin analogs are used to treat patients with moderate and advanced PAH and PAH is further categorized to functional class II to IV by New York Heart Association (NYHA).8 Notably, epoprostenol (approved in 1995), treprostinil (approved in 2002), and iloprost (approved in 2003) are 3 proposed prostacyclins, acting both in potent promotion of vasorelaxation and in suppression of vascular smooth muscle development. The clinical efficacy of beraprost remains to be confirmed.4

It remains unclear which prostacyclin analog is superior as a vast majority of the many randomized clinical studies (RCTs) compared 1 prostacyclin analog to placebo without any comparisons among the current analogs.9–13 The consequent pairwise meta-analyses founded on the RCTs; therefore, merely estimated the correlation between prostacyclins and analogs and the 4 prostnoids were sometimes combined to be compared with ERAs and PDE-5Is, which necessitated the adoption of network meta-analysis among the 4 prostanoids which is able to figure out the most suitable prostnoid-associated regime for patients with severe PAH.14–16

Thus, the current study intended to pool eligible RCTs quantitatively by means of network meta-analysis. The regimes, namely, epoprostenol, treprostinil, iloprost, and beraprost, were

Editor: Mistiaen Wilhelm.
Received: September 30, 2015; revised: December 24, 2015; accepted: December 28, 2015.
From the Department of Cardiovascular Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, PR China.
Correspondence: Jun Wang, The Department of Cardiovascular Surgery, The First Hospital of Hebei Medical University, No 89 Donggang Road, Shijiazhuang, PR China (e-mail: hbmu_wj@163.com).
The authors have no funding and conflicts of interest to disclose.
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000002575
then ranked in descending/ascending order based on their efficacy, manifested as 6-min walk distance (6MWD), mortality, functional class (FC) amelioration, and discontinuation of PAH patients.

MATERIAL AND METHODS

Literature Identification

RCTs related to epoprostenol, beraprost, treprostinil, and iloprost were systematically retrieved from Pubmed, Embase, Cochrane library, and CNKI (up to August 1, 2015). The following search terms were used: “epoprostenol” or “treprostinil” or “iloprost” or “beraprost” or “prostanoid” matched with “hypertension, pulmonary” or “pulmonary hypertension” or “pulmonary arterial hypertension” or “PAH.” Additional relevant references from identified articles were manually searched. No ethical approval was required for this study.

Inclusion Criteria

Studies conforming to the following requirements were included in the pool: (1) RCTs involving 4 prostacyclin analogs that reported at least one of following efficacy endpoints: 6MWD, NYHA functional class, all-cause mortality, and discontinuation of patients; (2) patients were definitely diagnosed with group 1 PAH according to the clinical classification of PAH; (3) documentations with incomplete and replicated data or outside the range of RCTs were elucidated.

Data Extraction

Two reviewers independently extracted the data; disagreements between them, if present, were resolved by consensus or with the help of the third reviewer. Extracted data mainly included baseline characteristics of treatment and control groups (eg sample size, PAH etiology), outcome measures (ie 6-MWD, death, FC amelioration, and discontinuation), and so on.

Endpoints

The 6MWD was formulated to count the distance walked by subjects on a flat and hard ground within 6 min.3,17,18 According to the World Health Organization (WHO) definitions, PAH is classified as follows: (1) none if pulmonary arterial systolic pressure (SPAP) is ≤30 mm Hg (1 mm Hg equals 0.1133 kPa); (2) mild if SPAP varies from 30 to 40 mm Hg; (3) moderate if SPAP is >40, yet <69 mm Hg; (4) severe if SPAP is ≥70 mm Hg.

Functional class (FC) amelioration occurs when SPAP is reversed from severe to moderate, from severe to mild, or from moderate to mild. All-cause mortality is defined as death contributed by all causes subjects. Discontinuation means that participants quit the study before it is over because of causes such as adverse effects.

Statistical Analysis

Pairwise meta-analysis was utilized to perform direct comparisons among the 5 interventions (placebo included); STATA 12.0 (Stata Corp, College Station, TX) software was used. The intergroup discrepancy with respect to continuous or dichotomous variable was evaluated by weighted mean difference (WMD) with a 2-tailed 95% confidence interval (CI) or an odds ratio (OR) with 2-tailed 95%CI, respectively. For studies failing to demonstrate mean and standard deviation of 6-MWD, values were manually estimated from available figures as proposed by Greenland and Zheng.19,20 The fixed-effect model and the random-effects model were utilized for consistent and heterogeneous studies, respectively. Interstudy heterogeneity was identified through Q test of Cochran (if $P_h < 0.05$)21 and test of $I^2$ (if $I^2 > 50$%).22 Network meta-analysis was later conducted in order to produce a mesh-like diagram based on incorporated studies. Each node is equivalent to 1 intervention; the bigger the node, the larger the sample size. The thickness of the line connecting 2 nodes represents the accuracy of effect size (the inverse of variance) between the 2 interventions. Efficacy and safety outcomes of the interventions were ranked by the surface under the cumulative ranking curve (SUCRA); sizable SUCRA means favorable efficacy of the intervention.23

RESULT

Baseline Characteristics of the Included Studies

Fourteen RCTs were eventually selected from 765 potential reports after ruling out those irrelevant studies (Figure S1, http://links.lww.com/MD/A641). No head-to-head trials existed among the 14 RCTs and only parallel trials between 1 regimen and placebo were presented in the star-shaped network diagram (Figure S2, http://links.lww.com/MD/A641). Among the aggregate 2511 subjects with follow-up periods ranging from 8 to 48 weeks (Table 1), 1073 (42.73%) individuals suffered from IPAH and 632 (25.17%) individuals were diagnosed as APAH, whereas the rest of the population was not reported to have a definite type of PAH. Furthermore, 2511 (100%), 961 (38.27%), 131 (5.22%), 125 (4.98%), and 108 (4.30%) PAH patients were prescribed treprostinil, iloprost, beraprost, and epoprostenol, respectively; there were 2511 placebo takers as well. The extent to which PAH patients’ physical states were improved was judged by 6-MWD, NYHA functional class amelioration, all-cause mortality, and discontinuation of patients with ~2062 (82.12%), 1356 (54.00%), 2485 (98.96%), and 2511 (100.00%) individuals involved.

Pairwise Meta-Analysis

Epoprostenol and treprostinil were found to be noticeably correlated with elongated 6-MWD in comparison to placebo (SMD = 52.19 [95%CI: 24.28–113.39] and SMD = 30.15 [95%CI: 19.29–41.01]), respectively (Table 2). Moreover, virtually no advantages in reduction of all-cause mortality could be found between prostacyclin analogs (beraprost, epoprostenol, iloprost, and treprostinil) and placebo (all $P > 0.05$). For FC amelioration, only epoprostenol appeared to elevate the possibility of reversing the participants’ health from high to low degrees within the NYHA functional class when compared with placebo (OR = 39.22, 95%CI: 9.64–159.45). Finally, subjects taking treprostinil were more likely to withdraw from studies than those taking placebo (OR = 1.53, 95%CI: 1.13–2.08); no other prostacyclin analogs displayed pronounced advantages over placebo in their tolerance.

Network Meta-Analysis

Among the 4 prostacyclin analogs (Table 3), only epoprostenol exhibited outstanding merits over placebo in extension of 6-MWD, lowering of mortality and FC improvement (SWD = 69.28 [95%CI: 10.43–128.98], OR = 0.21 [95%CI: 0.03–0.90], and OR = 42.79 [95%CI: 10.63–301.98]) (Figure 1). Meanwhile, epoprostenol was found to be more
## TABLE 1. Summarized Characteristics of the Included Randomized Controlled Trials

| Author (Year) | Country | Trial Acronym | Study Size | PAH Etiology (%) | Follow-Up | Interventions (Sample Size) | Outcome Measures |
|---------------|---------|---------------|------------|------------------|-----------|-----------------------------|------------------|
| Jing (2013)   | China   | FREEDOM-M     | 349        | IPAH/FPAH (74), APAH (26) | 12 weeks | Treprostinil (233) vs placebo (116) | ✓ ✓ ✓ |
| Tapson (2013) | China   | FREEDOM-C2     | 310        | IPAH/FPAH (65), APAH (35) | 16 weeks | Treprostinil (157) vs placebo (153) | ✓ ✓ ✓ ✓ |
| Tapson (2012) | Italy   | FREEDOM-C      | 350        | IPAH/FPAH (66), APAH (34) | 16 weeks | Treprostinil (174) vs placebo (176) | ✓ ✓ ✓ ✓ |
| Hiremath (2010)| India  | TRUST         | 44         | IPAH (95), APAH (5) | 12 weeks | Treprostinil (30) vs placebo (14) | ✓ ✓ ✓ |
| McLaughlin (2010) | America | TRIUMPH I      | 235        | IPAH/FPAH (56), APAH (44) | 12 weeks | Treprostinil (115) vs placebo (120) | ✓ ✓ ✓ |
| Olschewski (2010) | Germany | –            | 63         | IPAH (63), Other (37) | 3 months | Iloprost (30) vs placebo (33) | ✓ ✓ ✓ |
| Oudiz (2004)   | America | –             | 470        | NA               | 12 weeks | Treprostinil (235) vs placebo (235) | ✓ ✓ ✓ |
| Barst (2003)   | Alabama | –             | 116        | IPAH (74), APAH (26) | 48 weeks | Benaprost (60) vs placebo (56) | ✓ ✓ |
| McLaughlin (2003) | Ireland | –            | 26         | PPH (100)        | 8 weeks | Treprostinil (17) vs placebo (9) | ✓ |
| Galie (2002)   | Germany | ALPHABET      | 130        | IPAH (48), APAH (52) | 12 weeks | Benaprost (65) vs placebo (65) | ✓ ✓ ✓ |
| Olschewski (2002) | Germany | –            | 203        | PPH (50.5), Other (49.5) | 12 weeks | Iloprost (101) vs placebo (102) | ✓ ✓ ✓ |
| Badesch (2000) | America | PHSSDSG       | 111        | APAH (100)       | 12 weeks | Epoprostenol (56) vs placebo (55) | ✓ ✓ ✓ |
| Barst (1996)   | America | PPHSG         | 81         | PPH (100)        | 12 weeks | Epoprostenol (41) vs placebo (40) | ✓ ✓ |
| Rubin (1990)   | America | –             | 23         | IPAH (100)       | 8 weeks | Epoprostenol (11) vs placebo (12) | ✓ |

APA = associated PAH; FPAH = familial PAH; IPAH = idiopathic PAH; NA = not available; PAH = pulmonary arterial hypertension; PPH = persistent pulmonary hypertension.

1 = 6-min walk distance; 2 = all-cause mortality; 3 = functional class amelioration; 4 = discontinuation.
treprostinil, and beraprost (OR = 1.24), iloprost (OR = 1.28) (Figure 2). Moreover, participants prescribed beraprost seemed to be more likely to drop out of the study than those prescribed treprostinil (OR = 1.30), epoprostenol (OR = 4.41), and iloprost (OR = 5.26) (Figure 3). Subtle differences existed in the outcome measure of fatalities, suggesting that treprostinil might be associated with elevated mortality rate than beraprost (OR = 1.24), iloprost (OR = 1.91), and epoprostenol (OR = 3.38) (Figure 4).

In addition, a series of rank grams drawn from SUCRA (Figures 5 and 6) supported the seemingly advantageous efficacy of epoprostenol over other prostacyclin analogs. Epoprostenol was ranked as the top spot for incremental 6MWD (89.00%), FC amelioration (99.75%), and decreased death rate (83.75%). Besides, it appears that iloprost might be the least tolerable.15,20,23

Despite statistical insignificance, 4 prostacyclin analogs (ie epoprostenol, treprostinil, iloprost, and beraprost) showed an upward trend in their effects on prolongation of 6-MWD, reducing mortality and enhancing FC amelioration (Table 3, Figure 5), which might be partly elucidated by their distinct bindings to the prostacyclin receptors.38 According to Clapp et al, lift of cAMP concentration could, in a way, reflect the effects elicited by PG12 as well as its receptor on restraining the proliferation of vascular smooth muscle cells. Treprostinil peaked in the generation of cAMP, followed closely by iloprost and lastly by beroprost.39,40 It has been hypothesized that the leading role of treprostinil and iloprost might stem from their involvement in extra pathways, other than their approaches

FIGURE 1. Indirect comparisons of 4 prostacyclin analogs and placebo according to 6-min walk distance.

Comparison	Beraprost vs Placebo	Epoprostenol vs Placebo	Iloprost vs Placebo	Treprostinil vs Placebo

WMD (95% CrI)
24.07 (-61.49, 109.40)
69.28 (10.43, 128.98)
25.04 (-32.81, 83.33)
35.56 (-0.16, 74.87)

Comparison	Iloprost vs Beraprost	Placebo vs Beraprost	Treprostinil vs Beraprost

WMD (95% CrI)
-24.07 (-101.21, 101.28)
24.07 (-99.40, 69.49)
11.40 (-80.55, 104.27)

Comparison	Beraprost vs Epoprostenol	Iloprost vs Epoprostenol	Placebo vs Epoprostenol	Treprostinil vs Epoprostenol

WMD (95% CrI)
-44.24 (-150.25, 58.14)
44.24 (-58.14, 150.25)
0.79 (-102.21, 101.28)
-33.8 (-101.98, 36.17)

Comparison	Beraprost vs Iloprost	Epoprostenol vs Iloprost	Placebo vs Iloprost	Treprostinil vs Iloprost

WMD (95% CrI)
-95%CI: 1.47–160.65) (Figure 3).

Comparison	Beraprost vs Placebo	Iloprost vs Placebo	Treprostinil vs Placebo

OR (95% CrI)
0.55 (0.04, 6.11)
0.21 (0.03, 0.90)
0.37 (0.04, 3.34)
0.71 (0.22, 1.85)

Comparison	Beraprost vs Epoprostenol	Iloprost vs Epoprostenol	Placebo vs Epoprostenol	Treprostinil vs Epoprostenol

OR (95% CrI)
0.37 (0.02, 7.84)
0.66 (0.02, 21.90)
1.81 (0.16, 24.62)
1.24 (0.09, 19.00)

Comparison	Beraprost vs Iloprost	Epoprostenol vs Iloprost	Placebo vs Iloprost	Treprostinil vs Iloprost

OR (95% CrI)
1.52 (0.04, 42.66)
0.55 (0.03, 0.90)
2.68 (0.30, 28.44)
1.91 (0.16, 23.17)

Comparison	Beraprost vs Treprostinil	Epoprostenol vs Treprostinil	Placebo vs Treprostinil	Treprostinil vs Treprostinil

OR (95% CrI)
0.81 (0.05, 11.38)
0.30 (0.04, 1.85)
0.52 (0.04, 6.08)
1.42 (0.54, 4.51)

FIGURE 2. Indirect comparisons of 4 prostacyclin analogs and placebo according to functional class amelioration.

**DISCUSSION**

PAH occurs when there exist expressionnal turbulences of thromboxane within human body, the excess production of which could lead to medial hypertrophy and in situ thrombosis.33 To counteract the disordered role of thromboxane, prostacyclin (PG12), synthesized with the help of PG12 synthase not only potently eases the multiplication of vascular muscle cells and restricts the formation of thrombosis and activation of platelet,34 but also augments cardiac output by raising contents of cyclic adenosine monophosphate (cAMP) within cardiomyocytes.12,35,36 Thus, in the absence of adequate PG12, the development of PG12 analogs seemed to be crucial for PAH patients. Previous pairwise meta-analyses confirmed that they were notably more efficacious than placebo.

Despite statistical insignificance, 4 prostacyclin analogs (ie epoprostenol, treprostinil, iloprost, and beraprost) showed an upward trend in their effects on prolongation of 6-MWD, reducing mortality and enhancing FC amelioration (Table 3, Figure 5), which might be partly elucidated by their distinct bindings to the prostacyclin receptors.38 According to Clapp et al, lift of cAMP concentration could, in a way, reflect the effects elicited by PG12 as well as its receptor on restraining the proliferation of vascular smooth muscle cells. Treprostinil peaked in the generation of cAMP, followed closely by iloprost and lastly by beraprost.39,40 It has been hypothesized that the leading role of treprostinil and iloprost might stem from their involvement in extra pathways, other than their approaches...
TABLE 2. Pairwise Meta-Analyses of Direct Comparisons Between Prostacyclin Analogs and Placebo for Treatment of PAH

| Treatment Comparisons | Results of Pairwise Meta-analysis |
|------------------------|----------------------------------|
|                        | No. of Studies | Total Participants | OR/SMD (95% CI) | $I^2$ (%) | $P_{(heter)}$ |
| 6-min walk distance    |                |                    |                  |          |              |
| Beraprost vs placebo   | 1              | 130                | 24.00 (4.01; 8.48) | –        | –              |
| Epoprostenol vs placebo| 2              | 192                | 52.19 (6.14; 13.39)| 94.80    | <0.01          |
| Iloprost vs placebo    | 2              | 266                | 25.16 (4.14; 54.46)| 95.30    | <0.01          |
| Treprostinil vs placebo| 5              | 1125               | 30.15 (9.29; 41.01)| 93.80    | <0.01          |
| All-cause mortality    |                |                    |                  |          |              |
| Beraprost vs placebo   | 2              | 246                | 0.64 (0.10; 4.01)  | 0        | 0.679          |
| Epoprostenol vs placebo| 3              | 215                | 0.42 (0.14; 1.27)  | 34.90    | 0.215          |
| Iloprost vs placebo    | 2              | 266                | 0.43 (0.08; 2.47)  | 0        | 0.410          |
| Treprostinil vs placebo| 6              | 1758               | 0.80 (0.44; 1.44)  | 0        | 0.794          |
| Functional class amelioration |            |                    |                  |          |              |
| Beraprost vs placebo   | 2              | 246                | 1.25 (0.66; 2.38)  | 29.70    | 0.233          |
| Epoprostenol vs placebo| 3              | 215                | 39.22 (9.64; 159.45)| 0        | 0.838          |
| Iloprost vs placebo    | 2              | 228                | 1.73 (0.88; 3.41)  | 44.20    | 0.181          |
| Treprostinil vs placebo| 3              | 631                | 1.42 (0.85; 2.40)  | 0        | 0.396          |
| Discontinuation        |                |                    |                  |          |              |
| Beraprost vs placebo   | 2              | 246                | 3.51 (0.83; 14.89) | 0        | 0.817          |
| Epoprostenol vs placebo| 3              | 217                | 1.06 (0.32; 3.49)  | 0        | 0.542          |
| Iloprost vs placebo    | 2              | 266                | 0.58 (0.25; 1.34)  | 47       | 0.127          |
| Treprostinil vs placebo| 6              | 1786               | 1.53 (1.13; 2.08)  | 0        | 0.613          |

CI = confidence interval, heter = heterogeneity, OR = odds ratio, PAH = pulmonary arterial hypertension, SMD = standard mean difference

**FIGURE 3.** Indirect comparisons of 4 prostacyclin analogs and placebo according to discontinuation.

**FIGURE 4.** Indirect comparisons of 4 prostacyclin analogs and placebo according to all-cause mortality.
All isomer. However, as the capacity to produce cAMP was not specifically manifested as hybrids of separately 2 and 4 stereo-isomers of iloprost and beraprost also lied in their conformations, of adenylul cyclase inhibition. In fact, the functional deviation induced by iloprost was unexpectedly reversed with the action could also be explained by the observation that cAMP elevation potently confined. Furthermore, the low position of beraprost through which amplification of muscle cells were further relieved PAH patients’ mean pulmonary artery pressure (mPAP) by nearly 11%, on average, which was much predominance of epoprostenol over other prostacyclins could be explained by the observation that cAMP elevation was always obviated in mechanism investigations for its far too profound explanations. cell proliferation, further study is required in order to provide definitely equivalent to the efficacy of prostacylins to suppress adverse effects generated in the course of clinically drug
tistics to PAH patients might be, to some extent, attributed to the prophylactic values for predicting survival status. The gradually rising tendency from iloprost, epoprostenol, the functional deviation of iloprost and beraprost also lied in their conformations, specifically manifested as hybrids of separately 2 and 4 stereo-isomers. However, as the capacity to produce cAMP was not definitely equivalent to the efficacy of prostacyclins to suppress cell proliferation, further study is required in order to provide profound explanations. As far as epoprostenol was concerned, the prostacyclin was always obviated in mechanism investigations for its far too short elimination of half-life (±6 min), yet clinical predominance of epoprostenol over other prostacyclins could not be underestimated. Observationally, PAH patients receiving epoprostenol walked a longer distance on average (47 m) than those receiving conventional therapies within 6 min, whereas treprostinil and iloprost enabled the participants to accomplish only 16-m and 36-m longer distances when compared with placebo, respectively. Similar to 6-MWD, epoprostenol, relieved PAH patients’ mean pulmonary artery pressure (mPAP) by nearly 11%, on average, which was much >1.3% which was contributed by treprostinil. Alterations of mPAP, an indicator of cardiopulmonary hemodynamic changes, have prognostic values for predicting survival status.

The gradually rising tendency from iloprost, epoprostenol to treprostinil, and beraprost for their unacceptable characteristics to PAH patients might be, to some extent, attributed to the adverse effects generated in the course of clinically drug administration (Table 3, Figure 6). Iloprost was generally

### TABLE 3. The Efficacy (6-min Walk Distance [MWD] and Functional Class [FC] Amelioration) and Safety (All-Cause Mortality and Discontinuation) of 4 Prostacyclin Analogs for PAH Treatment According to the Network Meta-Analysis Using Odds Ratio (OR), Standard Mean Difference (SMD), and Corresponding 95% Confidence Intervals (CIs)

| (a) 6MWD | Beraprost | 44.24 | (–58.14; 150.25) | –24.07 | 11.40 |
| --- | --- | --- | --- | --- | --- |
|  | Epoprostenol | –44.24 | (–102.21; 101.28) | –109.40; 61.49 | –80.55; 104.27 |
|  | Iloprost | –44.39 | –124.04; 35.77 | –128.98; 10.43 | –101.98; 36.17 |
|  | Placebo | –0.79 | 24.07 | 69.28 | 78.52 |
|  | Treprostinil | –(–101.28; 102.21) | –(–35.77; 124.04) | –(–83.33; 32.81) | –(–55.45; 78.52) |
| (b) All–cause mortality | Beraprost | 2.70 | (0.02; 7.84) | 0.66 | 1.81 |
|  | Epoprostenol | 0.13; 56.50 | (0.02; 21.90) | 1.83 | 4.79 |
|  | Iloprost | 0.55 | (0.11; 35.96) | 1.32; 29.13 | 0.54; 27.50 |
|  | Placebo | 0.05; 42.66 | (0.03; 9.13) | 0.21 | 0.37 |
|  | Treprostinil | 0.04; 6.11 | (0.03; 0.90) | 0.04; 3.34 | 0.22; 1.85 |
| (c) FC amelioration | Beraprost | 0.81 | 33.38 | –10.77 | 35.56 |
|  | Epoprostenol | 0.05; 11.38 | (0.04; 1.85) | (0.04; 6.08) | (0.54; 4.51) |
|  | Iloprost | 3.79 | 42.79 | 1.32; 301.98 | 10.43; 128.98 |
|  | Placebo | 0.79 | 27.71 | 1.56 | 1.61 |
|  | Treprostinil | 0.12; 4.04 | (0.94; 256.03) | (0.11; 4.80) | (0.16; 1.89) |
| (d) Discontinuation | Beraprost | 0.23 | 0.35 | 0.13; 4.12 | 0.32; 26.46 |
|  | Epoprostenol | 0.53; 43.49 | (0.02; 1.87) | (0.01; 0.68) | (0.03; 1.01) |
|  | Iloprost | 10.07 | 2.15 | (0.08; 2.05) | (0.20; 2.60) |
|  | Placebo | 5.26 | 1.14 | 0.54 | 1.53 |
|  | Treprostinil | 0.99; 39.84 | (0.38; 4.98) | (0.20; 1.49) | (0.09; 3.97) |
|  | (0.68; 26.46) | 0.75 | 0.34 | 0.65 | (0.13; 1.12) | (0.42; 1.10) |

The column-defining treatment is compared with the row-defining treatment.

associated with G-protein (Gs), linked with adenylate cyclase, through which amplification of muscle cells were further potently confined. Furthermore, the low position of beraprost could also be explained by the observation that cAMP elevation induced by iloprost was unexpectedly reversed with the action of adenyl cyclase inhibition. In fact, the functional deviation of iloprost and beraprost also lied in their conformations, specifically manifested as hybrids of separately 2 and 4 stereo-isomers. However, as the capacity to produce cAMP was not definitely equivalent to the efficacy of prostacyclins to suppress cell proliferation, further study is required in order to provide profound explanations.
deemed as a well-tolerated agent with gentle side effects (e.g., cough, headache, and flushing), which could be partially explained by its ability to circumvent reduction of systemic pressure and unmatched ventilation/perfusion.44–47 Surprisingly, the unfavorable effects produced by epoprostenol were evidently, yet not significantly, less than those induced by treprostinil. As epoprostenol was intravenously delivered in the 2 RCTs,24,32 fatal complications, such as bloodstream infection (BSI), thromboembolic incidents, and sepsis could occur due to the presence of central venous catheter and infusion pump involved in the intravenous delivery system.48 Hence, fairly close negatives between epoprostenol and treprostinil might be expected under the assumption that treprostinil was also administered intravenously or subcutaneously; additionally, infusion site pain and reactions were frequently encountered as well.49,50 Nonetheless, the duration of epoprostenol was circumscribed within 6 min in human blood for its comparatively swift hydrolyzation and enzymatic degradation, leaving more persistent access of PAH patients to epoprostenol than treprostobil necessary due to longer half-life of treprostinil (2–4 h) and thus more severe unfavorable reactions were presented.8 More than that, the number (679) of subjects prescribed oral treprostinil was approximately 3 times higher than the overall number of participants who received treprostinil subcutaneously (235) and intravenously (47), further lowering the incidence of side reactions for treprostinil receivers.9,10,12,27,29 The disputed order of treprostinil and epoprostenol in induction of side effects may suggest that bias arising from small-scale studies incorporated in this NMA could affect the validity when treprostinil and epoprostenol were evaluated. Another explanation suggests that oral treprostinil was given before the effects of ERA/PDE-5I completely disappeared.

FIGURE 5. Surface under the cumulative ranking curve (SUCRA) of epoprostenol, treprostinil, iloprost, beraprost, and placebo according to 6-min walk distance (A), all-cause mortality (B), functional class amelioration (C), and discontinuation (D). The 5 possible ranks are on the horizontal axis, and the cumulative ranking probabilities (probability of each treatment to rank the first, the second best, and so on) are on the vertical axis. SUCRA = surface under the cumulative ranking curve.
implying that the overall effect of "combination therapies" was unpredictable and it might orient the unfavorable aspects of treprostinil in another direction.

Beraprost, which came last in each ranking, was still disapproved in Asia so far for its unsatisfying hemodynamics (http://clinicaltrials.gov identifier NCT00989963). A large proportion of PAH patients were in heritable forms and their modalities are correlated with connective tissue diseases, congenital heart disorder, and other systemic statuses.3,5 It was most likely the finite range of application that disabled implementations of RCTs among diverse ethnic groups, for which the downsides of beraprost remained undecided, making the last position of beraprost plausible.

This is the first network meta-analysis performed to compare multiple prostacyclin analogs for treating PAH. Although previous studies merely evaluated the efficacy of prostacyclin analogs beyond placebo, this NMA allows an all-round comparison of beraprost, epoprostenol, iloprost, and treprostinil through synthesizing indirect evidence for their common comparator of placebo within RCTs.51 Several flaws, nonetheless, really hindered our thorough evaluation of the 4 interventions.

First of all, 3 treprostinil-related RCTs were accompanied by ERA/PDE-5I administration beforehand, rendering therapeutic comparisons between treprostinil and other prostacyclins a bit ambiguous. Second, incomplete data gathered regarding outcome measures (ie 6-MWD, death, and FC amelioration) might influence the underlying efficacy/safety of beraprost, treprostinil, and epoprostenol. Dissimilar dosages of administrated drugs could be another contributing factor to less robust results. Furthermore, participants involved were followed up in short, different terms and with different doses of drugs; a long run study with stable and equal dosages could provide more convincing results. Finally, the cost-effective aspects of prostacyclins might be a considerable element that should be evaluated during clinical practice.

In conclusion, epoprostenol emerges as the most recommended prostacyclin analog due to its outstanding effects on 6-MWD, FC amelioration and reducing all-cause mortality. Due to the ideal clinical profile of epoprostenol, a durable mode was again developed and approved by FDA in 2008. Considering discordant settings of RCTs involved, extra clinical evidence should be obtained to perform a more accurate comparison among the 4 prostacyclin analogs.

FIGURE 6. Rankograms of epoprostenol, treprostinil, iloprost, beraprost, and placebo according to 6-min walk distance (A), all-cause mortality (B), functional class amelioration (C), and discontinuation (D). The 5 ranks on the vertical horizontal axis are shown in diverse colors: red (rank 1), thallite (rank 2), green (rank 3), blue (rank 4), and purple (rank 5). The corresponding ranking probabilities are on the vertical axis.
REFERENCES

1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. Turk Kardiyol Dern Ars. 2014;42(Suppl 1):45–54.

2. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:405–47S.

3. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015.

4. Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011;139:128–137.

5. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137:376–387.

6. Boutet K, Montani D, Jais X, et al. Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis. 2008;2:249–265.

7. Bazan IS, Fares WH. Pulmonary hypertension: diagnostic and therapeutic challenges. Ther Clin Risk Manag. 2015;11:1221–1233.

8. Framkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev. 2012;64:583–620.

9. Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144:952–958.

10. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142:1383–1390.

11. Olschewski H, Hooper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med. 2010;104:731–740.

12. Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;126:420–427.

13. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119–2125.

14. Coeytaux RR, Schmit KM, Kraft BD, et al. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 2014;145:1055–1063.

15. Biondi-Zoccai G, D’Ascenzo F, Cannillo M, et al. Choosing the best first line oral drug agent in patients with pulmonary hypertension: evidence from a network meta-analysis. Int J Cardiol. 2013;168:4336–4338.

16. Li T, Chen Y, Zang W, et al. Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis. Curr Med Res Opin. 2013;29:889–899.

17. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–1619.

18. Thenappan T, Glassner C, Gomberg-Maitland M. Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest. 2012;141:642–650.

19. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1–30.

20. Liao QB, Guo JQ, Zheng XY, et al. Test performance of sputum microRNAs for lung cancer: a meta-analysis. Genet Test Mol Biomarkers. 2014.

21. Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012;31:3805–3820.

22. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–680.

23. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8:e76654.

24. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med. 2000;132:425–434.

25. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296–301.

26. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496–1502.

27. Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010;29:137–149.

28. Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized, controlled trial. Circulation. 2013;127:624–633.

29. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55:1915–1922.

30. McLaughlin VV, Gaine SP, Rubin RJ, et al. Efficacy and safety of oral treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41:293–299.

31. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322–329.

32. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med. 1990;112:485–491.

33. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70–75.

34. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539–541.

35. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338:273–277.
36. Blumberg FC, Riegger GA, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. *Chest.* 2002;121:1566–1571.

37. Bai Y, Sun L, Hu S, et al. Combination therapy in pulmonary arterial hypertension: a meta-analysis. *Cardiology.* 2011;120:157–165.

38. Gomberg-Maitland M, Preston IR. Prostacyclin therapy for pulmonary arterial hypertension: new directions. *Semin Respir Crit Care Med.* 2005;26:394–401.

39. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. *Pharmacol Rev.* 1994;46:205–229.

40. Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. *Am J Respir Cell Mol Biol.* 2002;26:194–201.

41. Turcato S, Clapp LH. Effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cyclic AMP elevation in isolated guinea-pig aorta. *Br J Pharmacol.* 1999;126:845–847.

42. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. *Ann Intern Med.* 1991;115:343–349.

43. Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. *Eur Respir J.* 2010;35:1079–1087.

44. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. *Ann Intern Med.* 1996;124:820–824.

45. Olschewski H, Ghofrani HA, Walmrath D, et al. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. *Intensive Care Med.* 1998;24:631–634.

46. Olschewski H, Rohde B, Behr J, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. *Chest.* 2003;124:1294–1304.

47. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. *Ann Intern Med.* 2000;132:435–443.

48. Suszynski TM, Rizzari MD, Gillingham KJ, et al. Antihypertensive pharmacotherapy and long-term outcomes in pediatric kidney transplantation. *Clin Transplant.* 2013;27:472–480.

49. Skoro-Sajer N, Lang IM, Harja E, et al. A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension. *Clin Pharmacokinet.* 2008;47:611–618.

50. Mathier MA, McDevitt S, Sagar R. Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations. *J Heart Lung Transplant.* 2010;29:1210–1217.

51. Mills EJ, Ioannidis JP, Thorlund K, et al. How to use an article reporting a multiple treatment comparison meta-analysis. *JAMA.* 2012;308:1246–1253.